

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Review Proposal Project

### NICE Technology Appraisal TA457; Carfilzomib for previously treated multiple myeloma

#### Stakeholder list

##### **Consultees**

###### **Company/sponsor**

- Amgen (carfilzomib)

###### **Patient/carer groups**

- Black Health Agency
- Bloodwise
- Cancer Black Care
- Cancer Equality
- Cancer52
- Helen Rollason Cancer Charity
- Independent Cancer Patients Voice
- Leukaemia Cancer Society
- Leukaemia CARE
- Lymphoma Action
- Macmillan Cancer Support
- Maggie's Centres
- Marie Curie
- Muslim Council of Britain
- Myeloma UK
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus Cancer Care

###### **Professional groups**

- Association of Cancer Physicians
- British Committee for Standards in Haematology
- British Geriatrics Society
- British Psychosocial Oncology Society

- British Society for Haematology
- Cancer Research UK
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- UK Clinical Pharmacy Association
- UK Myeloma Forum
- UK Oncology Nursing Society

#### **Others**

- Department of Health and Social Care
- NHS Basildon and Brentwood CCG
- NHS Cambridgeshire and Peterborough CCG
- NHS England
- Welsh Government

#### **Commentators**

##### **General commentators**

- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare Products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Alliance
- NHS Confederation

- Scottish Medicines Consortium
- Welsh Health Specialised Services Committee

### **Comparators**

- Aspen (melphalan)
- Baxter (cyclophosphamide)
- Celgene (lenalidomide, pomalidomide)
- Hameln Pharmaceuticals (dexamethasone)
- Hospira (dexamethasone)
- Janssen (bortezomib)
- Merck Sharp & Dohme (dexamethasone)
- Napp pharmaceuticals (bendamustine)
- Novartis (panobinostat)
- Pfizer (cyclophosphamide)
- Rosemont Pharmaceuticals (dexamethasone)

### **Relevant research groups**

- Clinical Trials Research Unit
- Cochrane Haematological Malignancies Group
- Genomics England
- Institute of Cancer Research
- Leuka
- Leukaemia Busters
- MRC Clinical Trials Unit
- National Cancer Research Institute
- National Cancer Research Network
- National Institute for Health Research

### **Associated Public Health groups**

- Public Health England
- Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

